Grifols shrugs off Spanish stock market woes with 49% growth in 2011
This article was originally published in Clinica
Spanish biosciences group Grifols ended July as the best-performing stock so far this year on Madrid’s IBEX index of 35 leading shares. Its 49.5% share price rise (to €15.24) has taken place against a 2.3% contraction of the index (to 9,630 points) since the end of December 2010. The Barcelona-based group, which specialises in blood products, diagnostics (through its Diagnostic Grifols subsidiary) and hospital supplies, is also the third-best performing IBEX-35 stock over the last 12 months.
You may also be interested in...
Drawing on 24 years as a legislator and another 16 years as a leading lobbyist for biopharma, Jim Greenwood sees an opportunity for industry to put drug pricing ‘behind us’ with a legislative compromise.
SENZA PDN showed Nevro's HF10 spinal cord stimulation therapy provided sustained relief to patients with painful diabetic neuropathy. Results of a separate trial showed HF10 improved outcomes in patients with non-surgical refractory back pain.
No device-related warning letters were released by the US FDA the week of 19 January.